Pegamotecan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Pegamotecan
Accession Number
DB12842
Type
Small Molecule
Groups
Investigational
Description

Pegamotecan has been used in trials studying the treatment of Cancer of Stomach, Sarcoma, Soft Tissue, and Gastroesophageal Cancer.

Synonyms
Not Available
Categories
UNII
ZY7ZTE7LFH
CAS number
581079-18-7
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
Abicipar PegolThe therapeutic efficacy of Pegamotecan can be decreased when used in combination with Abicipar Pegol.
Antihemophilic Factor (Recombinant), PEGylatedThe therapeutic efficacy of Pegamotecan can be decreased when used in combination with Antihemophilic Factor (Recombinant), PEGylated.
Cepeginterferon alfa-2BThe therapeutic efficacy of Pegamotecan can be decreased when used in combination with Cepeginterferon alfa-2B.
Certolizumab pegolThe therapeutic efficacy of Pegamotecan can be decreased when used in combination with Certolizumab pegol.
Damoctocog alfa pegolThe therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegamotecan.
Egaptivon pegolThe therapeutic efficacy of Pegamotecan can be decreased when used in combination with Egaptivon pegol.
ElapegademaseThe therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegamotecan.
Eptacog alfa pegol (activated)The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Eptacog alfa pegol (activated).
GlycoPEG-GCSFThe therapeutic efficacy of Pegamotecan can be decreased when used in combination with GlycoPEG-GCSF.
Heptaethylene glycolThe therapeutic efficacy of Pegamotecan can be decreased when used in combination with Heptaethylene glycol.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911393

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2SuspendedTreatmentSoft Tissue Sarcoma (STS)1
2TerminatedTreatmentCancer of Stomach / Gastrooesophageal Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 20, 2016 18:38 / Updated on June 04, 2019 07:43